Algernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by Seyltx proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF) a Canadian clinical stage pharmaceutical development
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Algernon Pharmaceuticals Inc. reported earnings results for the first quarter ended November 30, 2023. For the first quarter, the company reported net loss was CAD 0.521554 million compared to CAD.
Algernon Pharmaceuticals Inc. announced that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for.